Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.

Sun K, Atoyan R, Borek MA, Dellarocca S, Samson ME, Ma AW, Xu GX, Patterson T, Tuck DP, Viner JL, Fattaey A, Wang J.

Mol Cancer Ther. 2017 Feb;16(2):285-299. doi: 10.1158/1535-7163.MCT-16-0390. Epub 2016 Dec 15.

2.

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.

Younes A, Berdeja JG, Patel MR, Flinn I, Gerecitano JF, Neelapu SS, Kelly KR, Copeland AR, Akins A, Clancy MS, Gong L, Wang J, Ma A, Viner JL, Oki Y.

Lancet Oncol. 2016 May;17(5):622-31. doi: 10.1016/S1470-2045(15)00584-7. Epub 2016 Mar 31.

3.

A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology.

Linden KG, Leachman SA, Zager JS, Jakowatz JG, Viner JL, McLaren CE, Barr RJ, Carpenter PM, Chen WP, Elmets CA, Tangrea JA, Lim SJ, Cochran AJ, Meyskens FL Jr.

Cancer Prev Res (Phila). 2014 May;7(5):496-504. doi: 10.1158/1940-6207.CAPR-13-0189. Epub 2014 Mar 10.

4.

A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.

Sabichi AL, Lee JJ, Grossman HB, Liu S, Richmond E, Czerniak BA, De la Cerda J, Eagle C, Viner JL, Palmer JL, Lerner SP.

Cancer Prev Res (Phila). 2011 Oct;4(10):1580-9. doi: 10.1158/1940-6207.CAPR-11-0036. Epub 2011 Aug 31.

5.

Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.

Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, Kang S, Linden KG, Heffernan M, Duvic M, Richmond E, Elewski BE, Umar A, Bell W, Gordon GB.

J Natl Cancer Inst. 2010 Dec 15;102(24):1835-44. doi: 10.1093/jnci/djq442. Epub 2010 Nov 29.

6.

A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.

Bailey HH, Kim K, Verma AK, Sielaff K, Larson PO, Snow S, Lenaghan T, Viner JL, Douglas J, Dreckschmidt NE, Hamielec M, Pomplun M, Sharata HH, Puchalsky D, Berg ER, Havighurst TC, Carbone PP.

Cancer Prev Res (Phila). 2010 Jan;3(1):35-47. doi: 10.1158/1940-6207.CAPR-09-0096.

7.

Conference Report: Seventh Annual AACR International Conference on Frontiers in Cancer Prevention Research.

Brown PH, Viner JL, Brewster A, Heckman CJ, Hursting S, Johnson K, Mao JT.

Cancer Prev Res (Phila). 2009 Nov;2(11):995-8. doi: 10.1158/1940-6207.CAPR-09-0128.

8.

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM.

Clin Cancer Res. 2009 Sep 1;15(17):5323-37. doi: 10.1158/1078-0432.CCR-09-0737.

9.

Statins in esophageal cancer cell lines: promising lead?

Hawk ET, Viner JL.

Am J Gastroenterol. 2008 Apr;103(4):838-41. doi: 10.1111/j.1572-0241.2007.01768.x. Epub 2008 Mar 24.

PMID:
18371147
10.

Workshop on imaging science development for cancer prevention and preemption.

Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee.

Cancer Biomark. 2007;3(1):1-33.

PMID:
17655039
11.

The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress.

Hawk E, Viner JL.

Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):185-7. No abstract available.

13.

Do statins prevent cancer?

Hawk ET, Viner JL.

Nat Clin Pract Oncol. 2006 Sep;3(9):478-9. No abstract available.

PMID:
16955084
14.

Celecoxib for the prevention of sporadic colorectal adenomas.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET; APC Study Investigators.

N Engl J Med. 2006 Aug 31;355(9):873-84.

15.

Statins and cancer--beyond the "one drug, one disease" model.

Hawk E, Viner JL.

N Engl J Med. 2005 May 26;352(21):2238-9. No abstract available.

PMID:
15917390
16.

The critical role of risk-benefit assessments in cancer prevention.

Hawk E, Viner JL.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):297-8. No abstract available.

17.

Can animal models help us select specific compounds for cancer prevention trials?

Hawk ET, Umar A, Lubet RA, Kopelovich L, Viner JL.

Recent Results Cancer Res. 2005;166:71-87. Review.

PMID:
15648184
18.

Prevention and therapy of colorectal cancer.

Hawk ET, Umar A, Richmond E, Viner JL.

Med Clin North Am. 2005 Jan;89(1):85-110, viii.

PMID:
15527810
19.

Irreversible ototoxicity associated with difluoromethylornithine.

Lao CD, Backoff P, Shotland LI, McCarty D, Eaton T, Ondrey FG, Viner JL, Spechler SJ, Hawk ET, Brenner DE.

Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1250-2.

20.

Colorectal cancer chemoprevention--an overview of the science.

Hawk ET, Umar A, Viner JL.

Gastroenterology. 2004 May;126(5):1423-47. Review.

PMID:
15131803
21.

Aspirin: still learning about the wonder drug.

Hawk ET, Viner JL.

Gut. 2003 Nov;52(11):1535-6. No abstract available.

22.

Chemoprevention of nonmelanoma skin cancer: experience with a polyphenol from green tea.

Linden KG, Carpenter PM, McLaren CE, Barr RJ, Hite P, Sun JD, Li KT, Viner JL, Meyskens FL.

Recent Results Cancer Res. 2003;163:165-71; discussion 264-6. Review.

PMID:
12903852
23.

Development of COX inhibitors in cancer prevention and therapy.

Umar A, Viner JL, Anderson WF, Hawk ET.

Am J Clin Oncol. 2003 Aug;26(4):S48-57. Review.

PMID:
12902856
24.

Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials.

Hawk ET, Viner JL, Umar A.

Prog Exp Tumor Res. 2003;37:210-42. Review. No abstract available.

PMID:
12795057
25.

Chemoprevention of skin cancer.

Richmond E, Viner JL.

Semin Oncol Nurs. 2003 Feb;19(1):62-9. Review.

PMID:
12638382
26.

Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer.

Steele VE, Hawk ET, Viner JL, Lubet RA.

Mutat Res. 2003 Feb-Mar;523-524:137-44. Review.

PMID:
12628511
27.

Epidemiology and prevention of colorectal cancer.

Hawk ET, Limburg PJ, Viner JL.

Surg Clin North Am. 2002 Oct;82(5):905-41. Review.

PMID:
12507200
28.

Chemoprevention of colorectal cancer: problems, progress, and prospects.

Viner JL, Umar A, Hawk ET.

Gastroenterol Clin North Am. 2002 Dec;31(4):971-99. Review.

PMID:
12489273
29.

COX-2 in cancer--a player that's defining the rules.

Hawk ET, Viner JL, Dannenberg A, DuBois RN.

J Natl Cancer Inst. 2002 Apr 17;94(8):545-6. No abstract available.

PMID:
11959883
30.

The role of cyclooxygenase inhibitors in cancer prevention.

Anderson WF, Umar A, Viner JL, Hawk ET.

Curr Pharm Des. 2002;8(12):1035-62. Review.

PMID:
11945150
31.

Chemoprevention of colorectal carcinogenesis.

Umar A, Viner JL, Richmond E, Anderson WF, Hawk ET.

Int J Clin Oncol. 2002 Feb;7(1):2-26. Review.

PMID:
11942045
32.

The future of colon cancer prevention.

Umar A, Viner JL, Hawk ET.

Ann N Y Acad Sci. 2001 Dec;952:88-108. Review.

PMID:
11795446
33.

Recommendations for cancer prevention trials using potentially ototoxic test agents.

Shotland LI, Ondrey FG, Mayo KA, Viner JL.

J Clin Oncol. 2001 Mar 15;19(6):1658-63.

PMID:
11250994
34.

Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and research.

Hawk ET, Viner JL.

Ann Intern Med. 2001 Jan 16;134(2):158-60. No abstract available.

PMID:
11177320
35.

Biomarkers as surrogates for cancer development.

Hawk E, Viner JL, Lawrence JA.

Curr Oncol Rep. 2000 May;2(3):242-50. Review.

PMID:
11122849
36.

Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin.

Shinohara H, Fan D, Ozawa S, Yano S, Van Arsdell M, Viner JL, Beers R, Pastan I, Fidler IJ.

Int J Oncol. 2000 Oct;17(4):643-51.

PMID:
10995873
37.

Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.

Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, Pastan I.

J Immunother. 2000 Jul-Aug;23(4):473-9.

PMID:
10916757
38.

Progress in cancer chemoprevention: development of diet-derived chemopreventive agents.

Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, Kopelovich L, Hawk ET, Lieberman R, Lawrence JA, Ali I, Viner JL, Sigman CC.

J Nutr. 2000 Feb;130(2S Suppl):467S-471S. doi: 10.1093/jn/130.2.467S. Review.

PMID:
10721931
39.

Progress in cancer chemoprevention.

Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Boone CW, Malone WA, Hawk ET, Lieberman R, Lawrence JA, Kopelovich L, Ali I, Viner JL, Sigman CC.

Ann N Y Acad Sci. 1999;889:1-13. Review.

PMID:
10668477
41.

[Modification of the non-shunting operation for bleeding esophageal varices].

Resnick SD, Burstein AE, Viner JL.

Harefuah. 1982 Mar 15;102(6):238-40. Hebrew. No abstract available.

PMID:
6984409

Supplemental Content

Loading ...
Support Center